Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA: Insulet Omnipod DASH Recall Deemed Class I

Executive Summary

Batteries used in the diabetes management devices may leak fluids or overheat, posing a potential fire risk. The recall, which the US FDA has now announced qualifies as high-risk class I, was first announced in October.

You may also be interested in...



Insulet Issues Safety Alert On Omnipod 5s Over Burn Risk

Cables and the charging port for the systems’ controller may overheat due to a poor connection, the company said. 

Battery Issues Result In Recall Of Insulet’s Omnipod DASH Diabetes Manager

Insulet has recalled its Omnipod DASH personal diabetes manager after reports from users of battery issues. The company says it is replacing the devices.

New Warning Label Added To AFX2 Endovascular Graft

The US FDA released updated safety information on Endologix Inc.’s AFX2 Endovascular abdominal aortic aneurysm (AAA) graft system on Tuesday. Previous devices in the product line have been associated with an increased risk of abnormal bleeding.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT146061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel